Advertisement

Peri-colonoscopy implications of SGLT2i therapy: A mini-review of available evidence

  • Venkatesan Thiruvenkatarajan
    Correspondence
    Corresponding author: Venkatesan Thiruvenkatarajan, , Department of Anaesthesia, Queen Elizabeth Hospital, 28 Woodville Rd, Woodville South, SA, 5011
    Affiliations
    Department of Anaesthesia, Queen Elizabeth Hospital, South Australia and Discipline of Acute Care Medicine, University of Adelaide, South Australia

    Basil Hetzel Institute, South Australia
    Search for articles by this author
  • Joshua M. Inglis
    Affiliations
    Department of Endocrinology and Diabetes, Queen Elizabeth Hospital, South Australia

    School of Medicine, University of Adelaide, South Australia

    College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia
    Search for articles by this author
  • Emily Meyer
    Affiliations
    Department of Endocrinology and Diabetes, Queen Elizabeth Hospital, South Australia

    School of Medicine, University of Adelaide, South Australia
    Search for articles by this author
  • Mahesh M. Umapathysivam
    Affiliations
    Department of Endocrinology and Diabetes, Queen Elizabeth Hospital, South Australia

    School of Medicine, University of Adelaide, South Australia
    Search for articles by this author
  • Nagesh Nanjappa
    Affiliations
    Department of Anaesthesia, Queen Elizabeth Hospital, South Australia and Discipline of Acute Care Medicine, University of Adelaide, South Australia

    Basil Hetzel Institute, South Australia
    Search for articles by this author
  • Roelof Van Wijk
    Affiliations
    Department of Anaesthesia, Queen Elizabeth Hospital, South Australia and Discipline of Acute Care Medicine, University of Adelaide, South Australia

    Basil Hetzel Institute, South Australia
    Search for articles by this author
  • David Jesudason
    Affiliations
    Basil Hetzel Institute, South Australia

    Department of Endocrinology and Diabetes, Queen Elizabeth Hospital, South Australia

    School of Medicine, University of Adelaide, South Australia
    Search for articles by this author
Published:December 23, 2022DOI:https://doi.org/10.1016/j.jcjd.2022.12.003
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are a class of oral glucose-lowering agents commonly used for the treatment of type 2 diabetes (T2D). With increased use there has been an increase in the incidence of the rare but life-threatening complication of euglycemic diabetic ketoacidosis. A common but underappreciated precipitant is colonoscopy. This review outlines the pathophysiology of the interaction between colonoscopy and SGLT2i use, the evidence regarding SGLT2i use in the periprocedural setting and society guidelines.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect